HARBOUR BIOMED

和鉑醫藥控股有限公司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

POSITIVE PROFIT ALERT

This announcement is made by HBM Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the "**SFO**").

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary review of the Group's unaudited management accounts for the six months ended 30 June 2026, the revenue for the six months ended 30 June 2026 is expected to be within the range of approximately US$120 million (equivalent to approximately HK$941 million) to approximately US$125 million (equivalent to approximately HK$980 million), as compared to a revenue of approximately US$101 million for the six months ended 30 June 2025. The profit for the six months ended 30 June 2026 is expected to be within the range of approximately US$62 million (equivalent to approximately HK$486 million) to approximately US$67 million (equivalent to approximately HK$525 million). Total adjusted profit[1] is expected to range between US$70 million (equivalent to approximately HK$549 million) and US$75 million (equivalent to approximately HK$588 million). The anticipated revenue growth and scaled profit are mainly attributable to:

– Continued strategic collaborations with leading global multinational pharmaceutical companies, such as the long-term strategic collaboration with AstraZeneca and the global strategic collaboration with Bristol Myers Squibb.

– Newly secured out-licensing and collaboration of innovative products, such as the licensing collaboration with Solstice Oncology, as well as the milestone payments triggered by the advancement of existing collaborations.

– Strong business growth of Nona Biosciences, including the revenue generated from antibody transaction and antibody discovery, such as the collaboration with Lonza.

Note:

1. Adjusted items of profit are mainly from share-based compensation expenses and other one-time expenses.

As of the date of this announcement, the Company is still in the process of finalizing the interim results of the Group for the six months ended 30 June 2026. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 currently available to the Company, and is not based on any figures or information which have been reviewed or confirmed by the audit committee of the Board (the "**Audit Committee**"), or reviewed or audited by the auditors of the Company. The actual results of the Group for the six months ended 30 June 2026 may differ from those disclosed in this announcement. They shall not be taken as a measure or indication of the Group's current or future operating or financial performance nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Company's interim results announcement for the six months ended 30 June 2026, which is expected to be published by the end of August 2026 in accordance with the requirements of the Listing Rules. As such, the above figures are provided for Shareholders' and investors' reference only. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended 30 June 2026.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors are advised to seek professional advice from professional or financial advisers.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 24 July 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.